learndrugs
Endocrine

Cushing’s Syndrome

Verified · Sep 2026

Cushing’s syndrome is the constellation of signs and symptoms produced by sustained hypercortisolism — excessive tissue exposure to cortisol or other glucocorticoids, most often from prescribed steroid medication rather than from a tumour.

The disorder behind moon face, buffalo hump, purple striae, the never-stop-steroids-suddenly rule, and the reason a patient on prednisone with a normal temperature can still be septic.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 The HPA axis, and the two ways it breaks

Cortisol is controlled by a three-storey feedback loop. The hypothalamus releases CRH, which drives the anterior pituitary to release ACTH, which drives the adrenal cortex to make cortisol — and cortisol then feeds back to shut CRH and ACTH down. Break the loop anywhere and cortisol runs high. Hypercortisolism is the clinical state of excessive tissue exposure to cortisol from exogenous or endogenous sources; Cushing’s syndrome is the collection of signs and symptoms that develops when it is sustained.

The single most important classification question is not "which tumour?" but "is there a prescription?" The most common cause of Cushing’s syndrome overall is iatrogenic — exogenous glucocorticoid administration by any route: oral, inhaled, topical, or parenteral. More than 10 million people in the United States receive pharmacologic doses of glucocorticoids each year. Exogenous exposure must be excluded before anyone investigates an endogenous cause.

When the cause is endogenous, it splits on ACTH. ACTH-dependent disease accounts for 60–70% — most of it a pituitary corticotroph adenoma, which earns the separate name Cushing’s disease (the syndrome is the picture; the disease is the pituitary subset, and it is the second most common cause overall after steroids). ACTH-independent adrenal disease is 10–20% — an adrenal adenoma, carcinoma, or hyperplasia making cortisol on its own. Ectopic ACTH is 6–10%, usually from a chest lesion, with small-cell lung carcinoma carrying the worst prognosis. Endogenous cases are diagnosed mostly between ages 30 and 49, and women are affected 3–4 times more often than men — but Cushing’s disease is typically diagnosed 3 to 6 years after symptoms begin, because the onset is so insidious that each change looks like ordinary weight gain.

The HPA axis with its cortisol negative feedback (dotted), and the four routes to hypercortisolism — one of which, exogenous steroid, simultaneously creates the syndrome and disables the axis.

02 One hormone, every tissue — the catabolic split

Cortisol excess does not do one thing; it does the same thing everywhere, and the result is a body divided against itself. Fat is redistributed centrally — truncal obesity, a dorsocervical fat pad ("buffalo hump"), a supraclavicular fat pad, and facial rounding — in a strictly dose- and duration-dependent way. At the same time cortisol activates proteolytic systems (ubiquitin-proteasome, cathepsins, calpains) that degrade myofibrillar protein, while its anti-anabolic effects block amino-acid transport, suppress IGF-I, and stop satellite cells differentiating. Type 2b fast-twitch fibres atrophy preferentially and type 1 fibres are relatively spared.

Put those two together and you get the phenotype exams describe as truncal-dominant, apple-on-sticks: fat gained centrally, muscle lost peripherally, so thin arms and legs carry a thickened trunk. Two details separate this from ordinary obesity at the bedside. First, the supraclavicular fat pad is more specific for hypercortisolism than the dorsocervical one — it is the more discriminating sign to document. Second, the muscle weakness comes with a typically normal creatine kinase: the fibres are being disassembled by proteolysis, not destroyed by inflammation, so the enzyme a nurse would expect to rise usually does not. CK, AST, LDH and aldolase are all typically normal here — though they may be elevated very early in the disease process, or in the acute steroid myopathy of critically ill patients, so a raised CK does not by itself overturn the diagnosis.

The same catabolism dismantles connective tissue. Collagen breakdown thins the skin until dermal capillaries show through as wide violaceous striae greater than 1 cm across the abdomen, thighs, upper arms and breasts, and brings easy bruising and impaired wound healing with it. In bone, up to 40% of patients on long-term glucocorticoids develop bone loss leading to fractures, and trabecular loss happens within the first 6 to 12 months — the damage starts long before anyone orders a bone-density scan. In metabolism, cortisol produces a dose-dependent rise in fasting glucose and a larger rise in postprandial values, through gluconeogenesis and insulin resistance, tipping impaired glucose tolerance into diabetes.

Cortisol excess acts on every tissue at once — building fat centrally while dismantling muscle, collagen and bone, which is what produces the truncal-dominant phenotype.

03 Mineralocorticoid spillover and a silenced immune system

At high concentrations cortisol stops respecting the boundary between glucocorticoid and mineralocorticoid activity. That spillover acts through the renin-angiotensin-aldosterone system to produce hypertension and hypokalemia — sodium and water retained, potassium wasted in the urine. Clinically that shows up as blood pressure that can be severe and resistant, a low potassium, fluid retention, and lower-limb edema. The lesson for the nurse is to check the potassium rather than assume that a tired, weak patient on steroids is simply deconditioned.

The immune consequence is more dangerous because it is invisible. Glucocorticoid inhibits cytokine release, which raises infection risk and blunts the signs that would normally announce it — patients "may not manifest common signs and symptoms of infection as clearly, due to the inhibition of cytokine release." The risk is quantifiable and dose-linked: prednisone below 10 mg daily poses minimal to no infection risk, and above that there is a linear increase with both dose and duration. So in a patient on steroids, the absence of fever is not reassurance. Any unexplained deterioration — hypotension, tachycardia, confusion, or simply "not right" — is treated as possible infection until proven otherwise.

One more mechanism explains a diagnostic test. In Cushing’s disease, "the frequency of ACTH production remains the same, but the normal circadian rhythm is lost" — cortisol fails to fall at night. That lost nocturnal nadir is exactly what the late-night salivary cortisol screen is designed to catch. And one sign sorts the causes: diffuse cutaneous hyperpigmentation suggests ACTH-dependent forms (pituitary, ectopic ACTH, ectopic CRH). It is absent in exogenous and adrenal disease, because in those there is no ACTH excess driving melanocytes.

04 The withdrawal trap — why one drug causes two syndromes

This is the concept that makes Cushing’s syndrome a nursing disorder rather than an endocrinology curiosity. A pharmacologic glucocorticoid directly suppresses ACTH and CRH secretion, and chronic suppression "leads to functional adrenal atrophy." So the patient on long-term prednisone is in two states at once: they look profoundly Cushingoid, and they cannot make cortisol if the drug is taken away. The same prescription that produced the syndrome will produce an adrenal crisis the moment it stops.

The rules that follow are specific. A course shorter than 14 to 21 days does not suppress the HPA axis and can be stopped without any taper. Beyond about three weeks, tapering is required — and the 2024 ESE/Endocrine Society joint guideline sets the at-risk threshold as duration of 3–4 weeks or more combined with any dose above a daily hydrocortisone equivalent of 15–25 mg (4–6 mg prednisone or prednisolone, 3–5 mg methylprednisolone, 0.25–0.5 mg dexamethasone). Tapering begins only once the underlying disease is controlled and the steroid is no longer needed, and it moves in guideline-sized steps: above 40 mg prednisone, 5–10 mg decrements weekly; at 10–20 mg, 2.5 mg every 1–4 weeks; at 5 mg, 1 mg every 4 weeks.

Two states get confused during a taper and must be separated. Glucocorticoid withdrawal syndrome — arthralgias, myalgias, weakness, fatigue, sleep disturbance and mood change — happens while the dose is still above physiologic, and is managed by going back to the last tolerated dose and slowing the taper. Adrenal insufficiency appears only when the dose becomes subphysiologic or inadequate for the stress the patient is under, and its symptoms are frustratingly non-specific: weakness, malaise, nausea, vomiting, diarrhoea, abdominal pain, headache, fever, anorexia, myalgia, psychiatric change — all of which "can be mistaken for symptoms of intercurrent illness." The same trap closes after curative surgery: the tumour’s cortisol is gone, but the suppressed normal axis has not recovered.

Why the same drug causes both syndromes: chronic glucocorticoid produces the Cushingoid picture and an atrophied adrenal cortex, so stopping abruptly removes the only available cortisol. Taper steps and the recovery threshold are from the 2024 ESE/Endocrine Society joint guideline.

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

Exogenous glucocorticoid by any route — oral, inhaled, topical, parenteral (the most common cause overall) modifiable Higher dose and longer duration — fat redistribution, infection risk and hypertension are all dose- and duration-dependent modifiable Fluorinated glucocorticoids (dexamethasone) — "much more potent" and more toxic than non-fluorinated agents modifiable Prednisone above 10 mg/day for 4 weeks or longer — the myopathy threshold (faster at 40–60 mg/day for 2–3 weeks) modifiable Concurrent NSAID on top of a glucocorticoid — 4-fold GI-bleed risk modifiable Pituitary corticotroph adenoma (Cushing’s disease) — mostly microadenomas < 10 mm; 5–10% are macroadenomas USP8 mutation — the most common driver in Cushing’s disease, raising growth-factor signalling and cortisol output Ectopic ACTH syndrome — most lesions in the chest; small-cell lung carcinoma carries the poorest prognosis Adrenal adenoma (0.6 per million person-years) or adrenal carcinoma (0.2 per million person-years) Adrenal incidentaloma — a screening trigger for hypercortisolism Age 30–49 at diagnosis for endogenous disease; women affected 3–4 times more often than men Pseudo-Cushing (physiologic hypercortisolism) mimics — pregnancy, morbid obesity, melancholic depression, chronic alcoholism, poorly controlled diabetes, eating disorders, obstructive sleep apnea, PCOS

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

Progressive centrally dominant weight gain with thin arms and legs early
Why: Cortisol redistributes fat to the trunk while proteolysis dismantles peripheral muscle — the two processes together produce the truncal-dominant, apple-on-sticks phenotype rather than uniform obesity.
Moon facies with facial plethora and malar telangiectasia
Why: Facial rounding is fat deposition, not fluid. The red, full look on top of it comes from skin thinning over dilated capillaries, so the flush and the roundness have two separate mechanisms.
Dorsocervical ("buffalo hump") and supraclavicular fat pads
Why: The same dose-dependent central fat redistribution. The supraclavicular pad is more specific for hypercortisolism than the dorsocervical one — it is the finding worth documenting precisely.
Wide violaceous striae > 1 cm on abdomen, thighs, upper arms and breasts
Why: Cortisol-driven collagen breakdown thins the dermis until capillaries show through the stretched skin. Width is what separates these from ordinary stretch marks — striae over 1 cm are a screening trigger for hypercortisolism.
Thin skin, easy bruising and poor wound healing Hold & notify
Why: Connective-tissue breakdown plus impaired healing. Easy bruising in a young patient is a specific screening trigger, and the fragile skin is why tape, shear and rough handling cause injury on this population.
Proximal muscle weakness — trouble climbing stairs or rising from a low chair Hold & notify
Why: Type 2b fibre atrophy from proteolysis. The hip girdle is affected earlier and more severely than the shoulders; weakness is symmetric with minimal or no pain, reflexes may be decreased, and there are no sensory or neurological deficits — with a typically normal CK (muscle enzymes may rise very early or in acute steroid myopathy of the critically ill).
Hyperglycemia or new/worsening diabetes
Why: Gluconeogenesis plus insulin resistance, raising fasting glucose and postprandial values more. It calls for glucose monitoring and treatment — never for stopping the steroid abruptly.
Hypertension — sometimes severe and resistant Hold & notify
Why: Mineralocorticoid spillover acting through the renin-angiotensin-aldosterone system. With prescribed corticosteroids it occurs usually at higher doses only; in Cushing’s disease it is one of the two major predictors of morbidity and mortality.
Hypokalemia with sodium retention, fluid retention and lower-limb edema Hold & notify
Why: The same mineralocorticoid effect wasting potassium in the urine while holding sodium and water. Check the potassium rather than attributing weakness and cramping to the steroid in general.
Frequent or severe infection with the usual signs missing Report immediately
Why: Glucocorticoid inhibits cytokine release, so patients may not mount fever or the typical inflammatory response. Risk rises linearly with dose and duration above 10 mg prednisone daily — which means absence of fever is not reassurance.
Mood and cognitive change — from euphoria to steroid psychosis Hold & notify
Why: Early therapy often brings an improved sense of well-being, mild euphoria or anxiety; depression is greater with longer therapy. Steroid psychosis occurs almost exclusively above 20 mg prednisone daily given for a prolonged period. Akathisia is common.
New hip, groin or knee pain — osteonecrosis or fragility fracture Hold & notify
Why: Trabecular bone is lost within the first 6–12 months of therapy, and osteonecrosis is seen especially with long-term prednisone above 20 mg daily, with hips and knees most commonly affected. Rib and vertebral fractures after trivial force are classic.
Silent cataracts and glaucoma late
Why: Cataract risk is significantly high above 10 mg prednisone daily for more than a year, bilateral and slowly progressive; steroid glaucoma raises intraocular pressure and is often painless, risking permanent optic-nerve damage. Screening cannot wait for symptoms.
Diffuse cutaneous hyperpigmentation — only in ACTH-dependent disease
Why: Excess ACTH stimulates melanocytes. Its presence points to a pituitary, ectopic-ACTH or ectopic-CRH source; it is absent in exogenous steroid and adrenal (ACTH-independent) Cushing’s syndrome, so it is a useful sorting sign.
New severe headache or loss of peripheral vision late Report immediately
Why: Mass effect from a pituitary macroadenoma. Most patients lack bitemporal hemianopsia because the lesions are typically microadenomas and only about 10% grow large enough to compress the optic chiasm — which makes new visual-field loss a significant finding, not an expected one.

Diagnostics

Test In this disorder Normal
Late-night (midnight) salivary cortisol Requires at least 2 measurements evaluating early-morning and late-night levels and the preservation of a normal diurnal rhythm. It is also the best predictor of recurrence after treatment, so it reappears at every follow-up Fails to fall at night — the lost diurnal nadir; sensitivity and specificity 95–98% Endocrine Society 2008 Cushing syndrome diagnosis guideline, as reported by StatPearls —
24-hour urinary free cortisol Collection starts with an empty bladder — discard the first morning void. Repeat (three collections) because hypercortisolism can be episodic. Falsely low if eGFR < 60 mL/min/1.73 m², and abnormal urine volume gives false results Abnormal when results are three times higher than normal free cortisol; specificity 81% Endocrine Society 2008 Cushing syndrome diagnosis guideline, as reported by StatPearls —
1-mg overnight dexamethasone suppression test Preparation trap: oral contraceptives and estrogens raise corticosteroid-binding globulin and cause false positives — they should be discontinued 6 weeks before. Confirm the dexamethasone was taken and absorbed with a concurrent serum dexamethasone level Give 1 mg dexamethasone at 11 PM, measure serum cortisol at 8 AM; above 1.8 µg/dL is abnormal (failure to suppress) Endocrine Society 2008 Cushing syndrome diagnosis guideline, as reported by StatPearls Suppressed cortisol < 1.8 µg/dL (50 nmol/L)
Plasma ACTH A value of 5–20 pg/mL is the grey zone and needs dynamic testing (CRH, desmopressin or metyrapone stimulation). DHEA-S moves with it: reduced in ACTH-independent disease, normal or increased in ACTH-dependent disease < 5 pg/mL is very strongly predictive of ACTH-independent disease → adrenal CT · > 20 pg/mL is highly suggestive of ACTH-dependent disease → pituitary MRI Endocrine Society 2008 Cushing syndrome diagnosis guideline, as reported by StatPearls —
Pituitary MRI (dynamic contrast-enhanced) A positive scan alone does not prove the source: nonfunctional microadenomas are found in 10–20% of healthy volunteers. Imaging is the third tier — screening and confirmation come first, and at least two abnormal first-tier tests are required Detects a corticotroph adenoma — but MRI fails to find a tumour in 40% of patients; the average detected tumour is about 6 mm —
Inferior petrosal sinus sampling Described as "the most validated strategy" for the pituitary-versus-ectopic question, but invasive and expensive — used selectively when imaging and biochemistry disagree Basal central-to-peripheral ACTH ratio over 3:1 with CRH administration separates pituitary from ectopic ACTH; sensitivity and specificity nearly 94% Endocrine Society 2008 Cushing syndrome diagnosis guideline, as reported by StatPearls —
Morning serum cortisol during a glucocorticoid taper Draw between 8:00 and 9:00 AM after holding the glucocorticoid dose for at least 24 hours. The guideline suggests against routine dynamic testing during a taper — this single morning level is the recommended first test > 300 nmol/L (10 µg/dL) = HPA axis recovered, glucocorticoid can be stopped · 150–300 nmol/L (5–10 µg/dL) = continue a physiologic dose, retest in weeks to months · < 150 nmol/L (5 µg/dL) = continue a physiologic dose, retest in a few months ESE / Endocrine Society 2024 joint guideline —

Complications

Warning: Adrenal crisis — the withdrawal emergency Report immediately
Hypotension, shock, decreased consciousness, lethargy, unexplained hypoglycemia, seizures, and even death — after an abrupt stop, a missed dose, or physiologic stress on a suppressed axis.
The suppressed axis cannot generate a cortisol surge. Symptoms are non-specific and "can be mistaken for symptoms of intercurrent illness": weakness, malaise, nausea, vomiting, diarrhoea, abdominal pain, headache, fever, anorexia, myalgia, psychiatric change. Parenteral glucocorticoid is required for moderate-to-major stress, procedures under general or regional anesthesia, prolonged inability to take oral medication, or signs of hemodynamic instability or prolonged vomiting or diarrhoea — and adrenal crisis should be considered irrespective of the glucocorticoid type, route, or dose (2024 ESE/Endocrine Society joint guideline). The same risk follows curative surgery, when the tumour’s cortisol is gone but the normal axis has not recovered.
Warning: Serious infection with the cues switched off Report immediately
The heralding cue is the absence of the usual cues: a patient on steroids who is hypotensive, tachycardic, confused, or simply "not right" — with or without fever.
Glucocorticoid inhibits cytokine release, so the fever and inflammatory signs that would normally trigger escalation may never appear. Risk climbs linearly with dose and duration above 10 mg prednisone daily and rises further with concurrent immunosuppressants. Treat any unexplained deterioration in a steroid patient as possible infection and escalate rather than waiting for a temperature.
Warning: Cardiovascular disease and venous thromboembolism Report immediately
Severe or resistant hypertension, accelerated atherosclerosis (coronary, cerebrovascular, peripheral), dilated cardiomyopathy, dyslipidemia — plus a prothrombotic state with raised DVT and pulmonary-embolism risk.
Long-term medium-to-high-dose glucocorticoid drives premature atherosclerosis in a dose-dependent pattern, and in Cushing’s disease "hypertension and the abnormalities of glucose metabolism are major predictors of morbidity and mortality." The thrombotic heralding cues are the familiar ones: unilateral calf swelling or pain, or sudden dyspnea with pleuritic chest pain — escalate immediately.
Caution: Fragility fracture, osteonecrosis and steroid myopathy
Up to 40% of patients on long-term glucocorticoids develop bone loss leading to fractures, with trabecular loss inside the first 6–12 months. The heralding cue is new hip, groin or knee pain, or sudden back or rib pain after trivial force.
Osteonecrosis is seen especially above 20 mg prednisone daily long-term, with hips and knees most affected. Layer on proximal hip-girdle weakness from myopathy — which develops above 10 mg prednisone daily for 4 weeks or longer, faster at 40–60 mg — and the fall-plus-fracture combination is why every fall in a steroid patient is treated as a potential fracture.
Caution: Recurrence and residual morbidity after cure
Hypercortisolemia recurs in about a third of patients after initial treatment (35% in children), and "normalization of cortisol reduces, but does not eliminate, excess morbidity and mortality."
Hypertension, diabetes, osteoporosis and neuropsychiatric disorders persist, and quality of life stays reduced for years after remission; children show residual decline in IQ and cognitive indices even after cure. Late-night salivary cortisol is the best recurrence predictor, and lifelong follow-up is essential. After bilateral adrenalectomy, watch also for Nelson syndrome — an ACTH-secreting macroadenoma in 8–29% of patients, diagnosed on average 15 years later.

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Corticosteroids
Endocrine · prednisone

The one class on this page that is the cause, not the treatment. Exogenous glucocorticoids are the most common source of Cushing’s syndrome, and every feature above is a magnified version of this class’s adverse-effect profile — which is why the class page and this page teach the same physiology from opposite ends. The nursing payload is the taper logic: a course under 14–21 days does not suppress the axis and needs no taper, while 3–4 weeks or more at any dose above 4–6 mg prednisone daily does, in decrements of 5–10 mg weekly above 40 mg, 2.5 mg every 1–4 weeks at 10–20 mg, and 1 mg every 4 weeks at 5 mg (2024 ESE/Endocrine Society joint guideline). Never stop abruptly — and note that the drugs used to treat endogenous Cushing’s syndrome are steroidogenesis inhibitors and receptor antagonists, an entirely different pharmacology from the steroids that caused the iatrogenic form.

Beyond medications

  • Exogenous cause → taper, not surgery. The management is a "carefully monitored reduction in glucocorticoid use, with the ultimate aim of total withdrawal," begun only once the underlying disease is controlled and the steroid is no longer required. A lower dose may control symptoms where full withdrawal is impossible, and gradual dose reduction is essential.
  • Transsphenoidal surgery is first-line for Cushing’s disease and offers the best potential for cure, performed endonasally or sublabially by a skilled pituitary neurosurgeon with appropriate support staff. (Vintage note, because it is easy to assume otherwise: the Endocrine Society’s own editions on this disorder are 2008 for diagnosis and a 2015 treatment update, both reaching this page through StatPearls — only the glucocorticoid-withdrawal guidance below is from a 2024 document.) Remission runs 65–90% for microadenomas and under 65% for macroadenomas. Reported complications in Cushing’s disease series: diabetes insipidus 15%, fluid and electrolyte abnormalities 12.5%, neurological deficits 5.6%, with worse outcomes over age 64.
  • The two post-transsphenoidal sodium problems, in order. Diabetes insipidus is the most frequently reported endocrine complication (incidence 5–35%), classically triphasic: polyuria and polydipsia in the first 48 hours, antidiuresis with hyponatremia around one week, then a polyuric phase that may be permanent — though in most cases it resolves spontaneously within 24 hours. SIADH occurs in 9–30% and is the leading cause of post-pituitary-surgery hyponatremia, typically presenting after postoperative day 5, treated with fluid restriction and, if symptomatic, hypertonic saline. CSF leak occurs in about 6 of 100 cases — bed rest and lumbar drain, with exploration and defect closure if it persists beyond 24 hours.
  • Adrenalectomy. Unilateral adrenalectomy is the best strategy for a unilateral adrenal adenoma, laparoscopically for adenomas under 6 cm. Bilateral adrenalectomy is a last resort: it cures the hypercortisolism immediately but commits the patient to lifelong glucocorticoid and mineralocorticoid replacement plus lifelong Nelson-syndrome surveillance.
  • Pituitary radiotherapy (conventional, stereotactic, radiosurgery or gamma knife) follows unsuccessful transsphenoidal surgery. It is most effective in children, with cure rates as high as 80–88%; the main complication is hypopituitarism, with growth-hormone deficiency in 36–68%. For ectopic ACTH, surgical resection of the lesion offers the best chance of cure, with medical management bridging until it is localized.
  • Bone protection for anyone on chronic glucocorticoid — optimize calcium and vitamin D and do regular weight-bearing exercise for every adult on prednisone 2.5 mg or more daily for more than three months.
  • Physical therapy for steroid myopathy — resistance and aerobic exercise is effective for modulating muscle atrophy. A 6-month monitored resistance-training regimen improved skeletal-muscle strength 400% to 600% in heart-transplant recipients on chronic glucocorticoids, so the weakness is not simply something to be endured.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment & monitoring
Before and during steroid therapy, screen for diabetes, hypertension, heart failure, cataracts and glaucoma, peptic ulcer disease, active infection, low bone density and psychiatric illness — and record body weight, height, blood pressure, DEXA bone density and an ophthalmological examination, plus CBC, glucose (fasting, 2-hour OGTT, HbA1c) and a lipid profile.
Why: Every one of those is a system cortisol damages. A baseline taken before the drug does its work is the only way to tell later whether a finding is new — and several of these complications are silent until they are advanced.
Run the glucose schedule: check glucose for at least 48 hours after glucocorticoids are started, then every 3–6 months for the first year and annually afterward; lipids one month after initiation, then every 6–12 months.
Why: Glucocorticoid raises fasting glucose and postprandial values more, in a dose-dependent way — the rise begins immediately, which is why the first monitoring window is measured in hours rather than months.
Reassess fracture risk at baseline and every 12 months, with DEXA ideally before or within six months of starting therapy in all adults aged 40 or over, plus a 10-year FRAX assessment.
Why: Trabecular bone loss happens within the first 6–12 months and up to 40% of long-term users fracture — so a scan ordered a year into therapy has already missed the window when the loss occurred.
Arrange an annual ophthalmological examination, especially for anyone with cataract symptoms — and do not wait for eye pain.
Why: Steroid cataracts are bilateral and slowly progressive above 10 mg prednisone daily for over a year, and steroid glaucoma raises intraocular pressure often painlessly while risking permanent optic-nerve damage. Symptoms arrive too late to be the trigger.
Treat any new fever, hypotension, tachycardia, confusion, or unexplained deterioration in a steroid patient as possible infection and escalate — and in children on chronic glucocorticoid, plot growth every six months on a growth curve.
Why: Cytokine inhibition blunts the signs of infection, so absence of fever proves nothing; in children the red flag is weight crossing percentile lines upward while linear growth flattens or arrests, which is most pronounced with daily rather than alternate-day therapy.
Check the potassium when a steroid patient reports weakness, cramping or new edema — and document the supraclavicular fat pad, not only the dorsocervical hump.
Why: Mineralocorticoid spillover wastes potassium while retaining sodium and water, so weakness may be hypokalemia rather than myopathy. The supraclavicular pad is the more specific sign for hypercortisolism and therefore the more useful one to record.
Interventions & safety
Never stop a chronic glucocorticoid abruptly — hold the taper plan, and if a patient has already stopped, treat that as an active risk rather than a completed decision.
Why: Abrupt cessation of chronic glucocorticoid therapy risks HPA-axis suppression and can precipitate life-threatening secondary adrenal insufficiency. A course under 14–21 days needs no taper; beyond 3–4 weeks at any meaningful dose, a slow taper is what prevents adrenal crisis.
If taper symptoms appear — arthralgias, myalgias, weakness, fatigue, sleep disturbance, mood change — recognize glucocorticoid withdrawal syndrome and anticipate returning to the last tolerated dose and lengthening the taper.
Why: Withdrawal syndrome occurs while the dose is still above physiologic and is not the same as adrenal insufficiency, which appears only when the dose becomes subphysiologic or inadequate for stress. Separating them decides whether the answer is to slow down or to escalate.
Anticipate parenteral glucocorticoid for moderate-to-major stress, anesthesia, prolonged inability to take oral medication, hemodynamic instability, or prolonged vomiting or diarrhoea.
Why: A suppressed axis cannot generate the surge that stress demands, and the oral route fails exactly when the patient is vomiting. Adrenal crisis is considered irrespective of the steroid type, route or dose the patient was on.
Handle skin gently — minimize tape trauma and shear — assess fall risk at every shift, and treat any fall in a steroid patient as a potential fracture.
Why: Three mechanisms stack: thin skin with poor wound healing, proximal hip-girdle weakness that makes rising and transferring unsafe, and trabecular bone loss that turns a minor fall into a fragility fracture.
Review for a concurrent NSAID on any patient taking a glucocorticoid, and report melena, hematemesis or severe abdominal pain immediately.
Why: Corticosteroid plus NSAID carries a 4-fold increased risk of GI bleeding, and the same class also causes gastritis, ulcer, pancreatitis and visceral perforation — the last being a surgical emergency.
After transsphenoidal surgery, monitor serum sodium and urine output serially for 48 hours, watch for neurological deterioration, epistaxis, visual dysfunction, diabetes insipidus and hypotension from acute hypocortisolism, and expect bladder catheterization and a postoperative morning cortisol and prolactin.
Why: Diabetes insipidus is the most frequent endocrine complication and follows a triphasic pattern, while SIADH typically appears after postoperative day 5 — so a sodium that looks fine at discharge is not the end of the story, which is why the day-7 level is reviewed at follow-up.
Watch for and report clear nasal drainage after pituitary surgery — a cerebrospinal fluid leak, which occurs in about 6 out of 100 cases. Meanwhile management is bed rest and a lumbar drain, and a leak persisting beyond 24 hours may require exploration and defect closure.
Why: It belongs on the same surveillance list as the sodium and the urine output, and it is the complication most likely to bring this patient back — CSF leak is the single largest cause of 30-day readmission after this operation, at 4.1%, ahead of epistaxis at 3.1% and hyponatremia at 2%. The 24-hour mark is a decision point rather than a period of watchful waiting, so when the drainage is first reported changes what happens next.
Patient teaching
Teach — and re-teach — that these medications must never be stopped suddenly, and that any taper happens under medical supervision.
Why: This is the single most important teaching point on the page. Patients stop steroids precisely because the visible side effects distress them, and that decision is what converts a manageable syndrome into an adrenal crisis.
Arrange a medical alert bracelet, teach injectable emergency glucocorticoid administration, and include at least one family member or primary caregiver in every education session.
Why: Adrenal crisis presents with confusion and collapse — states in which the patient cannot explain their own steroid history or self-administer. The bracelet and the trained family member are what deliver the information and the injection when the patient cannot.
Explain the multisystem impact of cortisol excess — central obesity, hypertension, glucose intolerance or diabetes, osteoporosis, skin fragility, mood disturbance and increased infection risk — and that some complications persist after remission.
Why: Understanding why the monitoring schedule exists is what sustains adherence to it, and setting the expectation early prevents the demoralization of discovering after cure that hypertension, diabetes, osteoporosis and mood symptoms have not simply disappeared.
Teach the principle of the lowest effective dose for the shortest period needed to achieve treatment goals, and to report any infection promptly while avoiding known exposures.
Why: Risk of infection, myopathy, cataracts, psychosis and osteonecrosis all rise with dose and duration — so dose-minimizing is itself a clinical intervention. And because the usual signs may be absent, the patient reporting early is often the only warning available.
For anyone on prednisone 2.5 mg or more daily for longer than three months, teach calcium and vitamin D optimization plus regular weight-bearing exercise — and refer for supervised resistance training where myopathy is present.
Why: Bone loss begins in the first 6–12 months, so protection starts with the prescription rather than after the first fracture. Supervised resistance training is not merely tolerable — a 6-month regimen improved strength 400–600% in chronic-glucocorticoid patients.
Address body image and mood directly — the moon face, central weight gain, striae, hirsutism and bruising are visible, and depression, anxiety and behaviour change are part of the disorder. Involve mental-health professionals, nutritionists and rehabilitation specialists.
Why: The appearance changes are not cosmetic trivia; they are a documented part of the clinical picture, and the psychiatric effects are pharmacologic rather than a failure of coping. Naming both keeps the patient in treatment instead of quietly abandoning it.

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    The cues that matter cluster into two groups. Iatrogenic Cushing’s syndrome: rounded plethoric face, supraclavicular and dorsocervical fat pads, wide purple striae, easy bruising, 9 kg of central weight gain, proximal weakness she demonstrates by pushing out of the chair, hypertension at 168/96, glucose 212, and potassium 3.1. Unmet monitoring: no DEXA and no eye examination despite eight months above 10 mg daily. The most dangerous cue is not on the vitals sheet at all — it is her sentence about Friday. And one finding is a clue rather than a problem: the normal creatine kinase alongside real proximal weakness, which is exactly what steroid myopathy looks like.

  2. 2
    Analyze cues

    Every physical finding maps to one mechanism. Cortisol redistributes fat centrally while proteolysis strips type 2b fibres from the hip girdle — fat gained centrally, muscle lost peripherally, with a normal CK because the fibres are being disassembled rather than destroyed. Collagen breakdown thins the skin into wide violaceous striae and easy bruising. Mineralocorticoid spillover through the renin-angiotensin-aldosterone system explains both the 168/96 and the potassium of 3.1 — they are one finding, not two. Gluconeogenesis with insulin resistance explains the 212. Her dose and duration also place her above three documented thresholds: above 10 mg daily for over 4 weeks (myopathy), above 10 mg daily for over a year approaching (cataract risk), and above 20 mg daily for a prolonged period (psychosis and osteonecrosis risk). And eight months of therapy is far past the 14–21 day point below which no taper is needed.

  3. 3
    Prioritize

    Rank by what kills fastest. Priority one is the plan to stop on Friday. Eight months of prednisone at 20 mg has suppressed CRH and ACTH and produced functional adrenal atrophy — she looks Cushingoid and cannot make cortisol. Abrupt cessation risks hypotension, shock, hypoglycemia, decreased consciousness and death. Priority two is the ibuprofen, because corticosteroid plus NSAID carries a 4-fold GI-bleed risk and nobody has reconciled her medication list. Priority three is the hypokalemia and hypertension. The overdue DEXA and eye examination matter but are the slowest-moving items, and the moon face itself — the thing she came in about — is the least urgent finding of all.

  4. 4
    Generate solutions

    Do not argue with her about the face; agree with the goal and correct the method. Explain that the medicine has switched off her own adrenal production, so stopping suddenly leaves her with no cortisol at all — and that the way to get her face back is a supervised taper, which is a plan, not a refusal. Notify the prescriber to start a structured taper now that the arteritis is controlled, anticipating 2.5 mg decrements every 1–4 weeks in her 10–20 mg range once she comes down from 20, with morning cortisol checks along the way. Reconcile the ibuprofen. Order the overdue DEXA and ophthalmology referral. Address the potassium and blood pressure. Arrange a medical alert bracelet and teach emergency injectable glucocorticoid with a family member present.

  5. 5
    Take action

    Teach first, because the teaching is the intervention: "Please do not stop on Friday. The prednisone has told your adrenal glands to stop making cortisol, and they have shrunk. If you stop suddenly you could have no cortisol at all — that causes dangerously low blood pressure, confusion and collapse. The way we shrink the moon face is to come down slowly, on a plan, with blood tests." Then the SBAR: "54-year-old on prednisone 20 mg daily for 8 months for giant cell arteritis, with florid iatrogenic Cushing’s syndrome — BP 168/96, glucose 212, potassium 3.1, proximal weakness with a normal CK. She intends to self-discontinue this week. She is also on ibuprofen three times daily. Requesting a structured taper plan, potassium and blood-pressure management, NSAID review, and overdue DEXA and ophthalmology referrals." The trap to avoid is validating "just stop it" as a reasonable patient choice, or reassuring her that the side effects mean the dose is simply too high and she can cut it herself.

  6. 6
    Evaluate

    Success over the next weeks: she is still taking prednisone, now on a written taper she can describe back to you; the ibuprofen is stopped or replaced; potassium and blood pressure are being treated; DEXA and eye examination are booked; she wears the bracelet and a family member has handled the emergency injection kit. The re-escalation triggers are memorized in advance and taught to her: hypotension, confusion, collapse, unexplained hypoglycemia, or persistent vomiting — that is adrenal crisis, and it needs emergency care, not a call to the clinic in the morning. The second alarm is any unexplained deterioration with or without fever, because her steroid dose has blunted the signs of infection.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Rheumatology clinic · 1030, routine three-month review

A 54-year-old woman with giant cell arteritis, on prednisone 20 mg daily for the past 8 months. She brings a list of complaints and an announcement: she has read about the side effects, she hates what the medicine has done to her face, and she has decided to stop taking it at the end of the week.

Vitals — BP 168/96 · HR 88 · RR 16 · T 36.8 °C · weight up 9 kg since starting therapy
Assessment — rounded, plethoric face · supraclavicular and dorsocervical fat pads · wide purple striae across the abdomen · scattered ecchymoses on both forearms · cannot rise from the exam chair without pushing off with her arms
Labs — random glucose 212 mg/dL · potassium 3.1 mEq/L · creatine kinase within normal limits
Chart — no DEXA scan on file · no ophthalmology visit since starting prednisone · ibuprofen 400 mg three times daily added by urgent care six weeks ago for knee pain
Patient statement — "I am going to stop the prednisone this Friday. I want my face back."
Q1 Select all that apply
Which findings require follow-up in this patient? Select all that apply.
  1. A. Her stated plan to stop prednisone at the end of the week
  2. B. Potassium 3.1 mEq/L
  3. C. Ibuprofen 400 mg three times daily alongside prednisone
  4. D. Creatine kinase within normal limits
  5. E. Rounded, plethoric facial appearance
Reveal answer & rationale
Answer: A, B, C
Stopping a chronic glucocorticoid abruptly after eight months risks life-threatening adrenal insufficiency, so the plan itself is the most urgent finding (A). Hypokalemia is the mineralocorticoid spillover of hypercortisolism and needs correction (B). Corticosteroid plus NSAID carries a 4-fold increased GI-bleed risk, so the ibuprofen requires reconciliation (C). The normal CK (D) is expected, not a problem — steroid myopathy strips type 2b fibres by proteolysis rather than destroying them, so the enzyme stays normal; a raised CK would point somewhere else. The moon face (E) is a real finding but it is fat redistribution, it is not dangerous, and it is the item requiring the least urgent follow-up on this list.
Q2 Multiple choice
The patient says, "The steroids gave me this face, so stopping them is the fastest way to fix it." Which response is best?
  1. A. "You are right that the medicine causes it — stopping is reasonable as long as you tell the doctor afterward."
  2. B. "The medicine has switched off your own cortisol production, so stopping suddenly could leave you with none at all. We shrink it by tapering on a plan."
  3. C. "The facial changes are fluid retention, so cutting back on salt will resolve them faster than changing the medicine."
  4. D. "Those changes are permanent, so stopping the prednisone now will not help either way."
Reveal answer & rationale
Answer: B
Chronic glucocorticoid directly suppresses CRH and ACTH and causes functional adrenal atrophy, so abrupt cessation can precipitate life-threatening secondary adrenal insufficiency — and the correct route to reversing the appearance is a supervised taper (B). Option A endorses exactly the action that causes adrenal crisis. Option C states a falsehood the exam loves: moon facies is fat redistribution, not fluid retention, so a low-salt diet does not address it. Option D is both wrong and demoralizing — normalizing cortisol reduces the features, even though it does not eliminate every long-term complication.
Q3 Put in order
Put the nurse’s first four actions in priority order:
  1. A. Order the overdue DEXA scan and make the ophthalmology referral
  2. B. Teach the patient not to stop the prednisone and confirm she will continue until a taper plan is written
  3. C. Notify the prescriber with an SBAR requesting a structured taper, potassium and blood-pressure management, and NSAID review
  4. D. Document the Cushingoid findings and the updated plan of care
Reveal answer & rationale
Correct order: B → C → A → D
The only imminent life threat is the self-discontinuation, and preventing it requires no order — teach first and secure her agreement (B). Escalation follows immediately, because the taper plan, the potassium, the blood pressure and the NSAID all need prescriber decisions (C). The overdue screening (A) addresses real but slower-moving complications — bone loss and silent cataracts and glaucoma. Documentation (D) is essential but never precedes protecting the patient. Notifying first (C before B) leaves her walking out of the clinic still planning to stop on Friday.
Q4 Multiple choice
Three days later the patient calls: she stopped the prednisone anyway, and now feels weak and nauseated, has vomited twice, and "feels faint standing up." The nurse should recognize these findings as:
  1. A. Expected glucocorticoid withdrawal syndrome — reassure her and continue the taper
  2. B. A viral gastroenteritis unrelated to the medication change
  3. C. Possible adrenal crisis — she needs emergency evaluation now
  4. D. Rebound of her giant cell arteritis — schedule an urgent clinic visit next week
Reveal answer & rationale
Answer: C
Weakness, nausea, vomiting and orthostatic symptoms after abrupt cessation of long-term glucocorticoid are adrenal crisis until proven otherwise, and the condition progresses to hypotension, shock, decreased consciousness, hypoglycemia, seizures and death (C). The symptoms are famously non-specific and "can be mistaken for symptoms of intercurrent illness," which is exactly the trap in option B. Option A confuses two different states: glucocorticoid withdrawal syndrome occurs while the dose is still above physiologic and presents as arthralgias, myalgias, fatigue and mood change — not vomiting with near-syncope in a patient who has taken nothing for three days. Option D delays care by a week; note also that the vomiting itself makes oral replacement unreliable, so parenteral glucocorticoid is indicated.
Q5 Multiple choice
A colleague asks why this patient, whose temperature is 36.8 °C, is still considered at high risk for serious infection. The best explanation is:
  1. A. Her normal temperature confirms she has no infection; the risk is theoretical
  2. B. Glucocorticoid inhibits cytokine release, so fever and the usual inflammatory signs may be absent even during serious infection
  3. C. Infection risk only becomes significant once prednisone exceeds 60 mg daily
  4. D. Her risk comes from the hyperglycemia alone, so it resolves once glucose is controlled
Reveal answer & rationale
Answer: B
Glucocorticoid inhibits cytokine release, so patients "may not manifest common signs and symptoms of infection as clearly" — which means a normal temperature carries no reassurance and any unexplained deterioration is treated as possible infection (B). That directly refutes option A. Option C inverts the sourced threshold: prednisone below 10 mg daily poses minimal to no risk, and risk increases linearly with dose and duration above that — at 20 mg daily for eight months she is well into the risk zone. Option D is incomplete: hyperglycemia is one contributor, but the cytokine-mediated immunosuppression is a separate mechanism that persists independently of glucose control.

Common questions

What causes cushing’s syndrome?
Common causes and risk factors include exogenous glucocorticoid by any route — oral, inhaled, topical, parenteral (the most common cause overall), higher dose and longer duration — fat redistribution, infection risk and hypertension are all dose- and duration-dependent, fluorinated glucocorticoids (dexamethasone) — "much more potent" and more toxic than non-fluorinated agents, prednisone above 10 mg/day for 4 weeks or longer — the myopathy threshold (faster at 40–60 mg/day for 2–3 weeks), concurrent nsaid on top of a glucocorticoid — 4-fold gi-bleed risk, and others.
What are the early signs of cushing’s syndrome?
Early findings include Progressive centrally dominant weight gain with thin arms and legs.
Which findings should a nurse report immediately in cushing’s syndrome?
Report immediately: Frequent or severe infection with the usual signs missing, New severe headache or loss of peripheral vision, Adrenal crisis — the withdrawal emergency, Serious infection with the cues switched off, Cardiovascular disease and venous thromboembolism. These signal deterioration that needs rapid intervention.
What is the difference between Cushing’s syndrome and Cushing’s disease?
Cushing’s syndrome is the clinical picture produced by cortisol excess from any source — prescribed steroids, a pituitary tumour, an adrenal tumour, or ectopic ACTH. Cushing’s disease is one specific subset: excess ACTH from an anterior-pituitary adenoma driving the adrenal glands to overproduce cortisol. Cushing’s disease accounts for most ACTH-dependent endogenous cases (60–70%) and is the second most common cause of the syndrome overall — behind prescribed glucocorticoids, which remain the single most common cause.
Why can steroids never be stopped suddenly?
Because the drug has already switched off the body’s own supply. A pharmacologic glucocorticoid directly suppresses ACTH and CRH, and sustained suppression causes functional adrenal atrophy — so the patient simultaneously looks Cushingoid and cannot make cortisol. Removing the drug leaves them with nothing, which can precipitate adrenal crisis: hypotension, shock, confusion, hypoglycemia, seizures, even death. A course under 14–21 days does not suppress the axis and needs no taper; at 3–4 weeks or more above roughly 4–6 mg prednisone daily, a supervised taper is what prevents the crisis.
Why is a normal temperature not reassuring in a patient taking steroids?
Glucocorticoid inhibits cytokine release, which both raises infection risk and removes the signs that would normally announce an infection — patients may never mount a fever. Risk rises linearly with dose and duration above 10 mg prednisone daily. So in a steroid patient, hypotension, tachycardia, confusion, or simply being "not right" is treated as possible serious infection and escalated, regardless of what the thermometer says.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.